Further analysis utilizing a publically available software (KM plotter service; https://kmplot.com/analysis) revealed a shorter survival of patients with Hpa2-high tumors in a large cohort of over 600 ER-positive, HER2-negative breast cancer patients (Fig. 1). This evidence concerns the gene ERBB2 and breast carcinoma.